期刊文献+

左氧氟沙星对黄芩苷血药浓度的影响 被引量:4

Effects of levofloxacin on the plasma concentration of baicalin in rats
下载PDF
导出
摘要 目的:研究口服抗生素药物左氧氟沙星对中药黄芩苷血药浓度的影响。方法:用HPLC-ECD方法测定左氧氟沙星(30 mg·kg^(-1),po,bid,给药4 d)和黄芩苷(34 mg·kg^(-1),po,给药一次)合并用药组与黄芩苷(34 mg·kg^(-1),po,给药一次)单独用药组大鼠在给予黄芩苷后不同时间的血浆黄芩苷浓度,比较两者的药动学参数。结果:合并用药组中黄芩苷的C_(max)=(485.73±217.57)ng·mL^(-1),AUC_(0-24h)=(5508.49±2374.16)ng·mL^(-1)·h;单独用药组中黄芩苷的C_(max)=(2645.62+601.42)ng·mL^(-1),AUC_(0-24h)=(28952.90±5731.42)ng·mL^(-1)·h。合并用药组的C_(max)和AUC_(0-24h)显著低于单独用药组(P<0.05)。结论:左氧氟沙星严重影响黄芩苷的血药浓度,提醒临床医生和患者应合理用药。 Objective: To study the interference of levofloxacin with absorption of baicalin in rats. Methods: The rats were randomly supplemented with a single close of baicalin alone (34 mg·kg^ -1 ,po) or combination of levofloxacin ( 30 mg·kg^ -1 ,po, bid, for 4 days) with baicalin ( 34 mg· kg^ -1, po, single dose). Plasma concentrations of two groups were monitored by HPLC with electrochemical detection (ECD). The pharmacokinetics parameters were calculated by statistical moment analysis. Results: The pharmaeokinetics parameters of the bi-drugs and mono-drug groups were Cmax (485.73 ± 217.57) vs. (2645.62 ±601.42)ng·mL^-1 and AUC0-24h (5508.49 ±2374.16)vs. (28952.90±5731.42)ng·mL^- 1· h ; the P values showed a statistical difference (P 〈 0. 05 ). Conclusion : Levofloxacin significantly interferes the absorption of baicilin.
机构地区 北京大学药学院
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第4期266-268,共3页 Chinese Journal of New Drugs
关键词 黄芩苷 左氧氟沙星 药物动力学 药物相互作用 baicalin levofloxacin pharmacokinetics drug interaction
  • 相关文献

参考文献11

  • 1车庆明,黄新立,李艳梅,张坤,赤尾光昭,服部征雄.黄芩苷的药物代谢产物研究[J].中国中药杂志,2001,26(11):768-769. 被引量:73
  • 2ZHOU YJ, CHE QM, XU SX, et al. Metabolites of baicalein in human urine [J]. Pharmazie,2000,55(8):626-627.
  • 3AKAO T, KAWABATA K, YANAGINSAWA E,a al. Aiealin,the predominant flavone glueuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the agiyeone and restored to its original form [J]. J Pharm Pharmacol, 2000,52(12):1563-1568.
  • 4小橋恭一.和漢藥配糖體に天然のプロドラツゲ腸内細菌の役割[J].汉方研究,1995,279(3);74—76.
  • 5石原三也.對腸内菌從有影醫的藥漢方藥並用情况調查[J].YAKUGAKUZASSHI,2002,122(9):95—701.
  • 6曹文庄,张晓丹.从药品注册的实践谈合理使用抗菌药的重要意义[J].中国药学杂志,2004,39(11):801-803. 被引量:46
  • 7KIM DH, JANG IS, LEE SW, et al. Bacterioides J-37, a human intestinal bacterium, produces α-glucuronidase [J]. Biol Pharm Bull, 1997,20(8):834-837.
  • 8SHU YZ, HATrORI M, AKAO T, et al. Metabolism of paconiflorin and related compounds by human intestinal bacteria Ⅱ. Structure of 7S-and 7R-paeonimetabolines Ⅰ and Ⅱ formed byBacteoides fragilis and Lactobacillus brevis [ J ]. Chem Pharm Bull( Tokyo), 1987,35(9):3726-3733.
  • 9HASEGAWA H, SUNG JH, MATSUMIYA S, et al. Main ginseng saponin metabolites formed by intestinal bacteria[J]. Plant Med, 1996,62(5):453-457.
  • 10YANG L, AKAO T, KOBASHI K, et al. Purification and characterization of a novel senmmide-hydrolyzing beta-glucoside from Bifidobacterium sp. strain SEN, a human intestinal anaerobe[J].Biol Pharrn Bull, 1996,19(5):705-709.

二级参考文献9

  • 1毛凤斐 朱家壁 等.黄芩甙人体内吸收研究[J].中成药研究,1981,12:6-6.
  • 2小桥恭一.-[J].和汉医药杂志,1998,15(1):1-1.
  • 3Zhou Y J,Pharmazie,2000年,55卷,8期,626页
  • 4小桥恭一,和汉医药学杂志,1998年,15卷,1期,1页
  • 5王本祥,现代中药药理学,1997年,301,299页
  • 6中国药典.一部,1995年,270页
  • 7Abe K,Chem Pharm Bull,1990年,38卷,1期,208页
  • 8毛凤斐,中成药研究,1981年,12卷,6页
  • 9赵科社.黄芩甙生产工艺改进[J].中成药,1990,12(11):2-3. 被引量:6

共引文献117

同被引文献49

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部